DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers

Authors

Silke Tribius (ORCID: https://orcid.org/0000-0001-7754-0257)
Sören Schnellhardt
Alexander Rühle (ORCID: https://orcid.org/0000-0003-2022-897X)
Mechthild Krause
Annett Linge
Panagiotis Balermpas
Markus Hecht
Christoph Süß
Marlen Haderlein
Head and Neck Cancer Expert Panel of the German Society of Radiation Oncology DEGRO
Simon Böke

Institutions

Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
University of Zurich (CH)
Helmholtz-Zentrum Dresden-Rossendorf (DE)
University Hospital Regensburg (DE)
Universitätsklinikum Erlangen (DE)
University Hospital of Zurich (CH)
Asklepios Klinik St. Georg (DE)
University Children's Hospital Tübingen (DE)
University Hospital Leipzig (DE)
University Hospital Carl Gustav Carus (DE)
University of Regensburg (DE)
University of Tübingen (DE)
Saarland University (DE)

Publication Details

Journal: Strahlentherapie und Onkologie
Published: 2026-02-17
DOI: https://doi.org/10.1007/s00066-026-02511-6
Primary Topic: Head and Neck Cancer Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers

Silke Tribius, Sören Schnellhardt, Alexander Rühle, Mechthild Krause et al.

Feb 17, 2026

Strahlentherapie und Onkologie

Head and Neck Cancer Studies

article

DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers

Silke Tribius, Sören Schnellhardt, Alexander Rühle, Mechthild Krause, Annett Linge, Panagiotis Balermpas, Markus Hecht, Christoph Süß, Marlen Haderlein, Head and Neck Cancer Expert Panel of the German Society of Radiation Oncology DEGRO, Simon Böke

February 17, 2026article en

Abstract

No abstract available for this paper.

Strahlentherapie und OnkologieVol. 202(4)

Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), University of Zurich (CH), Helmholtz-Zentrum Dresden-Rossendorf (DE), University Hospital Regensburg (DE), Universitätsklinikum Erlangen (DE), University Hospital of Zurich (CH), Asklepios Klinik St. Georg (DE), University Children's Hospital Tübingen (DE), University Hospital Leipzig (DE), University Hospital Carl Gustav Carus (DE), University of Regensburg (DE), University of Tübingen (DE), Saarland University (DE)

Good health and well-being

Openalex Percentile: Top 52%

Head and Neck Cancer Studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers — Silke Tribius, Sören Schnellhardt, et al. · Strahlentherapie und Onkologie (2026) | TGRS Research Map | TGRS